Format
Sort by

Send to

Choose Destination

Search results

Items: 12

1.

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.

Mäurer M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, Miller AE, Dive-Pouletty C, Bozzi S, O'Connor PW.

Mult Scler Relat Disord. 2016 May;7:33-40. doi: 10.1016/j.msard.2016.02.012.

2.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006.

3.

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group..

Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7.

PMID:
25192851
4.

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW.

J Neurol. 2014 Sep;261(9):1781-8. doi: 10.1007/s00415-014-7395-7.

5.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group..

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9.

PMID:
24461574
6.

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group..

Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821.

PMID:
24126064
7.

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L.

J Neurol. 2013 Oct;260(10):2472-80. doi: 10.1007/s00415-013-6979-y.

8.

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group..

Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723.

PMID:
23447359
9.

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS; Teriflunomide Multiple Sclerosis Trial Group..

Mult Scler. 2012 Nov;18(11):1625-32. doi: 10.1177/1352458512450354.

10.

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.

Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson TP, Miller A, Benzerdjeb H, Li H, Simonson C, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center..

Neurology. 2012 Jun 5;78(23):1877-85. doi: 10.1212/WNL.0b013e318258f7d4.

PMID:
22622860
11.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group..

N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.

12.
Items per page

Supplemental Content

Loading ...
Support Center